Drugs / Zoster Vaccine Recombinant
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05775718 | Oct 2023 → Jan 2028 expected | — | University of Colorado, Denver | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zoster Vaccine Recombinant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05775718 ↗ |
| Modality | Vaccine | “adjuvanted recombinant glycoprotein E (gE) herpes zoster (HZ) vaccine (Shingrix)” NCT05775718 ↗ |